US21900C3088
US21900C3088
CorMedix Inc.
Loading chart...
Company Profile
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Latest News

Zacks • 10/08/2026
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
MT Newswires • 09/23/2026
Oppenheimer Initiates CorMedix at Outperform With $15 Price Target

Insider Monkey • 09/08/2026
CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

GlobeNewswire • 09/01/2026
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

Zacks • 08/31/2026
CorMedix (CRMD) Upgraded to Buy: Here's Why
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
Company Profile
5
MetricsCountry
Region
Sector
Industry
Website
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
7/7 Very High
5Y Volatility
76.5% p.a.
Max Drawdown (5Y)
-62.6%
Sharpe Ratio (5Y)
0.08
Beta Factor
1.41
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (76.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -94.2% in the extended horizon.